Printer Friendly

FOREST LABORATORIES AND RHONE-POULENC RORER TERMINATE JOINT MARKETING OF DDAVP

 NEW YORK, Nov. 30 ~PRNewswire~ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that its DDAVP~Micturin joint marketing agreement with Rhone-Poulenc Rorer (NYSE: RPR) has been terminated effective Dec. 31, 1992.
 Forest said that it did not believe that discontinuing the joint marketing agreement on DDAVP would have a material impact on its earnings growth in the fourth quarter of fiscal 1993 or for fiscal 1994.
 -0- 11~30~92
 ~CONTACT: Kenneth E. Goodman, vice president-finance of Forest Laboratories, 212-421-7850~
 (FRX RPR)


CO: Forest Laboratories, Inc.; Rhone-Poulenc Rorer ST: New York IN: MTC SU:

PS -- NY041 -- 1939 11~30~92 12:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1992
Words:109
Previous Article:SOUTHLAND AND MCLANE COMPLETE PREVIOUSLY ANNOUNCED TRANSACTION
Next Article:COOPERS & LYBRAND APPOINTS CHARLES F. JACEY, JR., CLIENT SERVICE VICE CHAIRMAN FOR NEW YORK CLUSTER
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
RHONE-POULENC RORER AND CHUGAI TO CO-DEVELOP, CO-MARKET TAXOTERE(R) FOR JAPAN
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RPR AND ADAMS LABORATORIES ANNOUNCE AGREEMENT TO CO-PROMOTE SLO-BID(TM)(THEOPHYLLINE, EXTENDED-RELEASE CAPSULES)
RHONE-POULENC RORER CLOSES U.S. PORTION OF PREVIOUSLY ANNOUNCED OTC AGREEMENT WITH CIBA
THE IMMUNE RESPONSE CORPORATION REGAINS ALL RIGHTS TO HIV IMMUNOTHERAPEUTIC FROM RHONE-POULENC RORER INC.
Rhone-Poulenc Rorer Launches a Room-Temperature Formulation of DDAVP(R) Nasal Spray for Treatment of Primary Nocturnal Enuresis
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters